Endometrial cancer with tubal metastasis detected during laparoscopic surgery in a patient undergoing fertility-sparing treatment with medroxyprogesterone acetate: a case report and review of the literature

Imari Deura1,*, Yuko Nagasawa1, Ryo Kanamori1, Eriko Shiraishi1, Yuki Horage1, Shiho Kuji1, Tatsuru Ohara1, Nao Suzuki1

1Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, 216-8511 Kanagawa, Japan

*Correspondence: imari@marianna-u.ac.jp (Imari Deura)

DOI: 10.31083/j.ejgo.2021.03.2334

This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).

Submitted: 1 December 2020 Revised: 15 February 2021 Accepted: 22 February 2021 Published: 15 June 2021

Objectives: Medroxyprogesterone acetate (MPA) therapy is useful as a fertility-sparing treatment for early endometrial cancer, but it poses a risk of progression and recurrence during the treatment. We report a case of endometrial cancer with tubal metastasis after long-term MPA therapy and review the literatures focusing on the failure of fertility-sparing treatment. Case: A nulliparous, 40 years old woman was started on MPA therapy after being diagnosed with grade 1 endometrioid carcinoma confined to the endometrium. She achieved complete remission after 10 months of treatment, but no pregnancy was established by assisted reproductive technology (ART). Eleven months after the first MPA therapy ended, atypical endometrial hyperplasia was confirmed. The disease was in remission again after the second MPA therapy for 8 months. The patient did not become pregnant by subsequent ART. Finally, a total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed. The gross pathological specimen revealed a 13 mm mass near the left uterine cornu. Histopathology showed a left tube metastasis. She was diagnosed with FIGO stage IIIA endometrial cancer and underwent the staging surgery by laparotomy. After the second surgery, adjuvant chemotherapy was initiated. After 13 months of disease-free survival, a recurrence was histologically detected at the vaginal stump. Following intracavitary radiation therapy, there was no evidence of disease for 10 months. Conclusions: The patient undergoing fertility-sparing treatment should be apprised of a risk of life-threatening progression of the disease. Once the patient has opted out of fertility preservation, definitive hysterectomy should be strongly recommended.

Keywords
Endometrial cancer; Fertility-sparing treatment; Laparoscopic surgery; Tubal metastasis; Vaginal stump recurrence

1. Introduction

Endometrial cancer is the most common gynecologic cancer in developed countries [1]. In Japan, cases have been increasing in recent years, with 9,673 cases reported in 2014 [2]. Although it presents most frequently in postmenopausal women, up to 7% of cases occur in patients younger than 45 years [3]. Fertility preservation is an important quality-of-life issue in these younger patients, but it poses a risk of progression of the disease. Fertility-sparing treatment with progestin is useful for atypical endometrial hyperplasia (AEH) and early-stage, well-differentiated endometrioid carcinoma confined to the endometrium [4]. For patients undergoing fertility-preserving treatment, medroxyprogesterone acetate (MPA) 400–600 mg/day is the recommended therapy [5].

We report a case of endometrial cancer with tubal metastasis detected during laparoscopic surgery after the remission induced by repeated fertility-sparing treatments and review the literatures focusing on the failure of fertility-sparing treatment.

2. Case report

The patient was a nulliparous woman with no previous significant medical history. At the age of 40, after being diagnosed with grade 1 endometrioid carcinoma, she was started on MPA therapy. Before the treatment, MRI findings showed an endometrial tumor without myometrial invasion. The details of the clinical history are shown in Fig. 1. During the initial treatment over 10 months, she achieved complete remission based on MRI findings and histological findings by whole endometrial curettage. After that, she underwent assisted reproductive technology (ART) including oocyte pick up with GnRH agonist short protocol and natural cycle frozen embryo transfer, but no pregnancy was established. Eleven months after the first MPA therapy ended, AEH was confirmed by pipelle endometrial biopsy, indicating that her disease had recurred. She resumed MPA therapy after receiving an explanation about its risk. After 8 months of treatment, the endometrial cancer was in remission again. ART was performed once more, but she did not become pregnant. Finally, the patient decided to stop fertility treatments at the age of 43.

Five months from the end of the second MPA course, given the risk of intrauterine recurrence, total laparoscopic hysterectomy with bilateral salpingo-oophorectomy (TLHBSO) was planned. Before the surgery, transvaginal ultrasonography findings showed an endometrial thickness of 4.2
mm and normal ovaries (Fig. 2). We confirmed no tumor in the uterus and no extraterine lesions in the pelvis using MRI (Fig. 2). There was no evidence of metastasis on contrast-enhanced CT findings. During laparoscopic surgery, we found a small lesion on the left fimbria (Fig. 3). The uterus and the ovaries appeared normal. No visible metastases were found in the abdominal cavity. The surgery was performed without intraoperative pathological diagnosis. Macroscopic findings of the surgical specimen showed a mass near the left uterine cornu and normal-appearing Fallopian tubes. The histopathological findings included a 13 mm flat tumor, grade 1 endometrioid carcinoma involving the uterine corpus. There was no myometrial invasion and no lymphovascular invasion. The findings on the Fallopian tubes showed grade 1 endometrioid carcinoma (Figs. 4,5). The peritoneal washing cytology was positive. The patient was diagnosed with advanced endometrial cancer, although we had considered the disease to be in remission after the second MPA therapy. A month after the first surgery, staging surgery by laparotomy, including retroperitoneal lymphadenectomy and omentectomy, was performed. The histopathological findings showed no metastases in the specimen. The postoperative diagnosis was FIGO stage IIIA endometrial cancer (pT3aN0M0). After the second surgery, six cycles of tri-weekly TC therapy (paclitaxel: 180 mg/m² + carboplatin: area under the curve = 6) were added as adjuvant chemotherapy. After 13 months of disease-free survival, a recurrence was histologically detected at the vaginal stump by the biopsy. After 24-Gy intracavitary radiation therapy, the patient has no evidence of disease for 10 months follow-up period.
3. Discussion

Current fertility-sparing treatment modalities include hormonal therapies involving oral progestins, progestin-releasing intrauterine devices, natural progesterone, oral contraceptives, selective estrogen receptor modulators, gonadotropin-releasing hormone agonist, and aromatase inhibitors [6]. Previous reports on progestin therapy for endometrial cancer revealed a high remission rate, but also a high relapse rate after remission (Table 1) (Ref. [4, 7–14]). In a meta-analysis of 408 cases with endometrial cancer, in which various types of fertility-sparing treatment were included and the patients treated were not limited to grade 1 endometrioid carcinoma confined to the endometrium, the fertility-sparing treatment achieved a remission rate of 76.2% and a relapse rate of 40.6% [7]. Another meta-analysis of 445 patients with presumed stage IA, well-differentiated endometrial cancer without myometrial invasion showed a remission rate of 82.4% and a relapse rate of 25.0% [8]. Gunderson et al. [4] reported that initial response induced by progestin therapy was observed in 74.6% of 280 patients with endometrial cancer and the rate of recurrence after initial remission was 35.4%.

MPA is commonly used as a fertility-sparing treatment of patients with well-differentiated endometrial cancer without myometrial invasion, particularly in Japan. Japanese studies regarding high dose MPA therapy reported a relapse incidence range of 22.0%–66.7% (Table 2) (Ref. [15–21]). A recent meta-analysis on MPA therapy revealed the pooled relapse rate was 33% (95% confidence interval, 18%–53%), although the patients with atypical endometrial hyperplasia were included in this study [22].

Levonorgestrel-releasing intrauterine device (LNG-IUD) has been used as a fertility-sparing treatment in recent years. According to a review, 17 of 37 patients with stage IA without myometrial invasion, grade 1 endometrial cancer achieved complete response rate of 46% (95% confidence interval, 29%–63%) [23]. Several studies reported the outcomes of the combination of progestin releasing IUD with oral progestin to achieve better outcomes than either agent alone [24–27]. Kim et al. [24] conducted a prospective study of patients with stage IA, grade 1 endometrial cancer confined to the endometrium who were treated with progestin-releasing IUD plus oral progestin. Out of 16 patients, 14 (87.0%) achieved complete response and only 2 (14.3%) had recurrent disease.

Progestin therapy has been performed in combination with medication and surgical regimes. Hysteroscopy provides direct visualization of the endometrial cavity thereby allowing a targeted biopsy or excision of the lesions iden-
Fig. 5. Histopathological findings of the uterus and the left Fallopian tube. (A) The findings of the uterine corpus; grade 1 endometrioid carcinoma, a 13 mm tumor without myometrial or lymphovascular invasion. (B) The findings of the left Fallopian tube: grade 1 endometrioid carcinoma.

Table 1. Literatures of fertility sparing treatment for endometrial cancer.

| Author (Year)   | Design       | Patients | Interventions     | Remission n (%) | Relapse n (%) |
|----------------|--------------|----------|-------------------|-----------------|--------------|
| Gallos (2012)  | Meta-analysis I–II (G1–3) | FST | 301/408 (76.2) | 89/267 (40.6) |
| Qin (2016)     | Meta-analysis IA (G1) | Oral progestin | 367/445 (82.4) | 92/367 (25.0) |
| Gunderson (2012) | Review IA (G1) | Progestin | 209/280 (74.6) | 74/209 (35.4) |
| Peiretti (2019) | Review IA (G1) | FST | 228/299 (76.0) | 77/228 (34.0) |
| Park (2013)    | Retrospective IA (G1) | Oral progestin | 115/148 (77.7) | 35/115 (30.4) |
| Wang (2018)    | Retrospective IA (G1) | FST | 161/170 (94.7) | 41/113 (36.3) |
| Yang (2019)    | Retrospective IA (G1) | HSR + Progesterone | 36/37 (97.3) | 4/36 (11.1) |
| Giampaolino (2019) | Retrospective IA (G1) | HSR + LNG-IUD | 11/14 (78.6) | 2/11 (18.2) |
| Mitsuhashi (2019) | Retrospective IA (G1) | Metformin + MPA | 40/42 (95.0) | 7/40 (17.5) |

I–II, FIGO stage I–II; IA, FIGO stage IA without myometrium invasion; G, grade of endometrioid carcinoma; FST, fertility sparing treatment; MPA, medroxyprogesterone acetate; HSR, Hysteroscopic resection; LNG-IUD, levonorgestrel-intrauterine device.

Hysteroscopic resection combined with progestin therapy may improve the result of fertility-sparing treatment for endometrial cancer patients. Yang et al. [12] reported the efficacy of hysteroscopic resection combined with progestin therapy in endometrial cancer patients. The patients had a remission rate and a relapse rate of 97.3% and 11.1%, respectively. The combination of hysteroscopic resection with LNG-IUD was also used as a fertility-sparing treatment of patients with endometrial cancer. Giampaolino et al. [13] showed a complete response rate of 78.6% and a relapse rate of 18.2%.

In addition, several reports confirmed the effects of metformin, which is a biguanide widely prescribed for the treatment of type 2 diabetes mellitus [29]. Mitsuhashi et al. [30] conducted phase II study of MPA plus metformin as a fertility-sparing treatment option for patients with endome-
trial cancer and reported long-term outcomes following the trial. Of 42 patients with endometrial cancer, 40 (95.0%) achieved complete response and 7 (17.5%) of the 40 patients relapsed. To date, many clinical trials of fertility-sparing treatment of endometrial cancer using the various types of combination therapy are underway [14].

After a complete remission, the patients wishing to conceive should be advised to pursue pregnancy earlier and consider ART to improve pregnancy rate [31]. The benefits of pregnancy on oncologic outcomes were reported by some literatures [32, 33]. Ichinose et al. [34] found that all patients who had receiving ART had a live birth and a low risk of recurrence compared to those who did not achieve pregnancy. Because of the high failure rate of hormonal treatment, it is currently recommended that a total hysterectomy is performed after completion of childbearing [31].

If a patient with recurrence after an initial treatment strongly desires the preservation of fertility, retreatment with progestin can be considered, but only under strict control [35]. Park et al. [10] showed a complete response rate of 85% and a recurrence rate of 18% to progestin re-treatment. In this report, the complete response rate to progestin retreatment is reported to range from 50% to 100% for recurrent disease. In the 2–4% of patients who undergo repeated MPA treatment for intrauterine recurrence, there is a risk of progression of cancer stage [36]. In our case, although the patient was diagnosed with complete remission after the second MPA therapy for intrauterine recurrence after the initial treatment, the recurrent intrauterine disease developed in the fallopian tubes.

Standard surgical treatment results in excellent oncologic outcomes, particularly for patients with presumed low-risk endometrial cancer. However, fertility-sparing treatment delays definitive treatment with a hysterectomy and poses a risk of life-threatening progression of the disease. Ruiz et al. [37] reported that women treated with hormonal treatment are 92% (HR = 1.92; 95% confidence interval, 1.15–3.19) more likely to die compared to patients undergoing primary hysterectomy.

There are few reports focusing on the disease progression after fertility-sparing treatment for presumed stage IA, well-differentiated endometrial cancer without myometrial invasion. Kaku et al. [15] reported that 2 of 9 responders with endometrial cancer developed relapse after MPA therapy and one of them had metastasis to the left obturator lymph node. The retrospective study of Ota et al. [17] showed that 8 patients received hysterectomy after MPA therapy and one of them died of the metastasis to the liver and the brain. The Gynecologic Oncology Group study evaluating the surgical pathologic features of 621 patients with stage I endometrial cancer showed that an appreciable number of patients (22%) have disease outside the uterus (lymph node metastasis, adnexal involvement, intraperitoneal spread and/or malignant cells in peritoneal washings). The adnexal involvement was detected in 5% of patients in the study [38]. A multicenter phase II study carried out at 16 institutions in Japan showed that one patient developing peritoneal carcinomatosis after repeated MPA therapy died of disease 4 months after staging surgery by laparotomy. The disease was speculated as synchronous malignancies of both endometrial and peritoneal carcinomas because there was no intrauterine recurrence 3 months before the development of the peritoneal lesions [19]. Synchronous ovarian cancer is seen in 5% of patients with endometrial cancer [39–41]. Several studies reported that synchronous ovarian cancer was detected in patients received hysterectomy after fertility-sparing treatment [19, 20].

To prevent a life-threatening progression of the disease after fertility-sparing treatment, it is important to select the appropriate candidates for the treatment. Selection of the appropriate candidates for fertility-sparing treatment depends on accurate cancer staging and histologic characteristics. MRI is essential to confirm eligibility by excluding myometrial invasion and tumor extension beyond the uterine corpus [42]. Histologic characteristics must be obtained by whole endometrial curettage since this approach is more accurate than endometrial biopsy for the assessment of tumor grade [43]. Our case was presumed stage IA, low-risk endometrial cancer before the first MPA therapy using MRI, CT, and whole endometrial curettage with hysteroscopy. The remission induced by the two courses of MPA therapy was evaluated using MRI and whole endometrial curettage.

---

**Table 2. Japanese literatures of MPA therapy for endometrial cancer.**

| Author (Year) | Design | Patients | Interventions | Remission n (%) | Relapse n (%) |
|---------------|--------|----------|---------------|----------------|--------------|
| Kaku (2001) [15] | Retrospective | IA G1–2 | MPA 200–800 mg/day | 9/12 (75.0) | 2/9 (22.0) |
| Imai (2001) [16] | Retrospective | I–II G1–2 | MPA 400–800 mg/day | 8/14 (57.1) | 3/8 (37.5) |
| Ota (2005) [17] | Retrospective | IA G1 | MPA 600 mg/day | 5/12 (42.0) | 2/5 (40.0) |
| Niwa (2005) [18] | Prospective | IA G1 | MPA 400–600 mg/day | 12/12 (100) | 8/12 (66.7) |
| Ushijima (2007) [19] | Prospective | IA G1 | MPA 600 mg/day | 14/22 (64.0) | 8/14 (57.0) |
| Yamazawa (2007) [20] | Prospective | IA G1 | MPA 400 mg/day | 7/9 (78.0) | 2/7 (22.0) |
| Minaguchi (2007) [21] | Prospective | IA G1 | MPA 400–600 mg/day | 14/18 (77.8) | 5/14 (35.7) |
| Total | | | | 69/99 (69.7) | 30/69 (43.5) |

IA, FIGO stage IA without myometrium invasion; I–II, FIGO stage I–II; G, grade of endometrioid carcinoma; MPA, medroxyprogesterone acetate.
Hysteroscopy was also used during the first MPA therapy course. As for the second MPA therapy course, it was possible that we could not detect the recurrent disease by MRI and whole endometrial curettage without hysteroscopy, because the intrauterine lesion was near the left uterine cornu. We should have used hysteroscopy to detect intrauterine recurrence, albeit with a potential increased risk of peritoneal spread during hysteroscopy. In a recent meta-analysis, although preoperative hysteroscopy resulted in a significant increase of positive peritoneal cytology, no impact on prognosis was observed [44]. In the present case, it was also difficult to detect the disease progression to the fallopian tubes before the first surgery. The laparoscopic findings were useful to detect the small lesion of the left fimbria, although there were not any macroscopic abnormalities from the surgical specimen. We doubted that the clinical stage of her endometrial cancer was revised to a higher stage, but TLHBSO was performed without an intraoperative pathological diagnosis as scheduled. As a result, the present case was diagnosed as advanced stage endometrial cancer and the recurrence was detected after the standard curative treatment, staging surgery followed by adjuvant chemotherapy. It is possible that the use of laparoscopic surgery for advanced stage endometrial cancer may be associated with local recurrence. We should have confirmed the tubal metastasis by intraoperative pathological diagnosis and converted the laparoscopic surgery to the staging surgery by laparotomy. Before the surgery, the patient should have been informed about the risk of progression of her disease and accepted the possibility of conversion to staging surgery.

4. Conclusions
We experienced a case of endometrial cancer with tubal metastasis detected during laparoscopic surgery after remission of the disease induced by repeated cycles of MPA therapy. As is well known, it is difficult to detect disease recurrence and progression during long-term MPA therapy. The patient undergoing fertility-sparing treatment should be apprised of a risk of life-threatening progression of the disease. Once the patient has opted out of fertility preservation, definitive surgery with curative intent should be strongly recommended as soon as possible.

Author contributions
ID designed the report and made the initial draft of the manuscript. YN and RK performed the research. TO, SK, and NS advised on deciding the treatment principles. All authors participated in constructing the manuscript and approved the final version.

Ethics approval and consent to participate
The Ethics Committee of St. Marianna University School of Medicine approved the study (Approved number: 4514). We obtained written informed consent from the patient according to the Declaration of Helsinki.

Acknowledgment
We gratefully acknowledge the work of past and present members of our department.

Funding
This research received no external funding.

Conflict of interest
The authors declare no conflict of interest.

References
[1] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015; 136: e359–e386.
[2] Saito T, Takahashi F, Katabuchi H, 2016 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology. Annual report of the committee on gynecologic oncology. Japan Society of Obstetrics and Gynecology: patients annual report for 2014 and treatment annual report for 2009. Journal of Obstetrics and Gynecology Research. 2017; 43: 1667–1677.
[3] Howlader N, Noone AM, Krapcho M, Miller D, Altekruse SF, et al. SEER cancer statistics review, 1975–2012. 2015. Available at: http://seer.cancer.gov/csr/1975_2012/ (Accessed: 9 September 2016).
[4] Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and Reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 Adenocarcinoma: a systematic review. Gynecologic Oncology. 2012; 125: 477–482.
[5] Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer diagnosis, treatment and follow-up. International Journal of Gynecological Cancer. 2016; 26: 2–30.
[6] Park JY, Nam JH. Progestin in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. Oncologist. 2015; 20: 270–278.
[7] Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology. 2012; 207: 266.e1–266.e12.
[8] Qin Y, Yu Z, Yang J, Cao D, Yu M, Wang Y, et al. Oral progestin treatment for early-stage endometrial cancer: a systematic review and meta-analysis. International Journal of Gynecological Cancer. 2016; 26: 1081–1091.
[9] Piretti M, congiu F, Ricciardi E, Maniglio P, Mais V, Angioni S. Conservative treatment of well-differentiated endometrial cancer: when and why it should be considered in young women. Ecancermedicalscience. 2019; 16: 1392.
[10] Park JY, Kim DY, Kim JH, Kim YM, KimKR, Kim YT, et al. Long-term outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). European Journal of Cancer. 2013; 49: 868–874.
[11] Wang Y, Yu M, Yang JX, Cao DY, Yuan Z, Zhou HM, et al. Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15 years experience. International Journal of Clinical Oncology. 2019; 24: 712–720.
[12] Yang B, Xu Y, Zhu Q, Xie L, Shan W, Ning C, et al. Treatment efficacy of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecologic Oncology. 2019; 153: 55–62.
[13] Giampaolino P, Sardo ADS, Mollo A, Rafffone A, Travaglini A, Boccelino A, et al. Hysteroscopic endometrial focal resection by
levonorgestrel intrauterine device insertion as a fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial cancer: a retrospective study. Journal of Minimally Invasive Gynecology. 2019; 26: 648–656.

[14] Mitsushashi A, Habu Y, Kobayashi T, Kawarai Y, Ishikawa H, Usui H, et al. Long-term outcomes of progesterin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients. Journal of Gynecologic Oncology. 2019; 30: e90.

[15] Kaku T, Yoshicawa H, Tsuda H, Sakamoto A, Fukunaga M, Kujwaba Y, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium young women: central pathologic review and treatment outcome. Cancer Letters. 2001; 167: 39–48.

[16] Imai M, Jobo T, Sato R, Kawaguchi M, Kuramoto H. MPA therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations. European Journal of Gynecological Oncology. 2001; 22: 217–220.

[17] Ota T, Yoshida M, Kiumara M, Kinoshita K. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. International Journal of Gynecological Cancer. 2005; 15: 657–662.

[18] Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG: An International Journal of Obstetrics & Gynaecology. 2005; 112: 317–320.

[19] Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. Journal of Clinical Oncology. 2007; 25: 2798–2803.

[20] Yamazawa K, Hirai M, Fujito A, Nishi H, Terauchi F, Ishikura H, et al. Fertility-preserving treatment with progesterin, and pathological criteria to predict responses, in young women with endometrial cancer. Human Reproduction. 2007; 22: 1953–1958.

[21] Minaguchi T, Nakagawa S, Takazawa Y, Nei T, Horie K, Fujitawa T, et al. Combined phosphor-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progesterin treatment in complex atypical hyperplasia and stage IA, GI adenocarcinoma of the endometrium. Cancer Letters. 2007; 248: 112–122.

[22] Wei J, Zhang W, Feng L, Gao W. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia. Medicine. 2017; 96: e6034.

[23] Baker J, Obermair A, Gebski V, Jana M. Efficacy of oral or intruterine device-delivered progesterin in patients with complex endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecologic Oncology. 2012; 125: 263–270.

[24] Kim MK, Seong SJ, Kim YS, Song T, Kim M, Yoon BS, et al. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer. American Journal of Obstetrics and Gynecology. 2013; 209: 358.e1–358.e4.

[25] Cade TJ, Quinn MA, Rome RM, Neesham D. Long-term outcomes after progesterone treatment for early endometrial cancer. The Australian & New Zealand Journal of Obstetrics & Gynaecology. 2013; 53: 566–570.

[26] Cade TJ, Quinn MA, Rome RM, Neesham D. Progesterone treatment options for early endometrial cancer. BJOG: An International Journal of Obstetrics and Gynaecology. 2010; 117: 879–884.

[27] Perri T, Korach J, Gotlieb WH, Beiner M, Meirod D, Friedman E, et al. Prolonged conservative treatment of endometrial cancer patients. International Journal of Gynecological Cancer. 2011; 21: 72–78.

[28] Angioni S, Loddo A, Milano F, Piras B, Minerba L, Melis GB. Detection of benign intracavitary lesion in postmenopausal women with abnormal uterine bleeding: a prospective comparative study on outpatient hysteroscopy and blind biopsy. Journal of Minimally Invasive Gynecology. 2008; 15: 87–91.

[29] Mitsushashi A, Shozu M. New therapeutic approaches for the fertility-sparing treatment of endometrial cancer. Journal of Obstetrics and Gynaecology Research. 2020; 46: 215–222.

[30] Mitsushashi A, Sato Y, Kiyokawa T, Koshizaka M, Hanaoka H, Shozu M. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Annals of Oncology. 2016; 27: 262–266.

[31] Colombo N, Creutzberg C, Querleu D, Barahona M, Sessa C. Appendix 5: Endometrial cancer: eUpdate published online 8 June 2017 (www.esmo.org/Guidelines/Gynecological-Cancers). Annals of Oncology. 2018; 28: iv153–iv156.

[32] Park J, Seong SJ, Kim T, Kim JW, Kim SM, Bae D, et al. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstetrics and Gynecology. 2013; 121: 136–142.

[33] Chae SH, Shim SH, Lee SJ, Lee JY, Kim SN, Kang SB. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrial cancer. International Journal of Gynecological Cancer. 2019; 29: 77–85.

[34] Ichinose M, Fujimoto A, Osuga Y, Minaguchi T, Kawanaka Y, Yan T, et al. The influence of infertility treatment on the prognosis of endometrial cancer and atypical complex endometrial hyperplasia. International Journal of Gynecological Cancer. 2013; 23: 288–293.

[35] Yamagami W, Mikami M, Nagase S, Tabata T, Kobayashi Y, Kaneuchi M, et al. Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms. Journal of Gynecological Oncology. 2018; 31: e18.

[36] Yamagami W, Susumu N, Makabe T, Saki K, Nomura H, Kataoka F, et al. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? Journal of Gynecologic Oncology. 2018; 29: e21.

[37] Ruiz MP, Huang Y, Hou JY, Tergas AJ, Burke WM, Ananth CV, et al. All-cause mortality in young women with endometrial cancer receiving progesterone therapy. American Journal of Obstetrics and Gynecology. 2017; 217: 669.e1–669.e13.

[38] Creasman WT, Morrow CP, Bundy BN, Hamesley HD, Graham JE, Hellor PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987; 60: 2035–2041.

[39] Anglesio MS, Wang YK, Massen M, Horlings HM, Bashashati A, Senz J, et al. Synchronous endometrial and ovarian carcinomas: evidence of clonality. Journal of the National Cancer Institute. 2016; 108: djv428.

[40] Schultheis AM, Ng CKY, De Filippo MR, Piscuoglio S, Macedo GS, Gatius S, et al. Massively parallel sequencing-based clonality analysis of synchronous endometrioid endometrial and ovarian carcinomas. Journal of the National Cancer Institute. 2016; 108: djv427.

[41] Song T, Seong SJ, Bae D, Suh DH, Kim D, Lee K, et al. Synchronous primary cancers of the endometrium and ovary in young women: a Korean Gynecologic Oncology Group Study. Gynecologic Oncology. 2013; 131: 624–628.

[42] Kinkel K, Kaji Y, Yu KK, Segal MR, Lu Y, Powell CB, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology. 1999; 212: 711–718.

[43] Leitao MM, Keohoe S, Barakat RR, Aletieri K, Gattoc LP, Rabbit C, et al. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecologic Oncology. 2009; 113: 105–108.

[44] Chang YN, Zhang Y, Wang YJ, Wang LP, Duan H. Effect of hysteroscopy on the peritoneal dissemination of endometrial cancer cells: a meta-analysis. Fertility and Sterility. 2011; 96: 957–961.